Table 2.
Promising Drugs in the T2D Pipeline8
| Product Developer(s) | Therapeutic Class | Mode of Administration | Expected Pricing Strategy | Anticipated U.S. Launch Date |
|---|---|---|---|---|
| Ertugliflozin Pfizer/Merck | SGLT-2 inhibitor | Oral tablet (once daily) | Priced at 10% discount to marketed SGLT-2 inhibitors | 2017 |
| FIAsp* Novo Nordisk | Insulin (ultra-rapid insulin aspart) | SC injection (before meal) | Priced at a 10% premium to NovoLog | 2017 |
| ITCA 650 Intarcia Therapeutics | Technology platform: continuous SC delivery of exenatide | Implanted SC osmotic mini-pump | Priced at 20% premium to Victoza | 2017 |
| OG217SC (oral semaglutide) Novo Nordisk | GLP-1R agonist | Oral tablet (once weekly) | Priced at 15% premium to Victoza | 2020 |
| Semaglutide Novo Nordisk | GLP-1 agonist | SC injection (once weekly) | Priced at 10% discount to dulaglutide | 2018 |
*
Fast-acting version of NovoLog.
DPP-4 = dipeptidyl peptidase 4; GLP-1 = glucagon-like peptide-1; GLP-1R = GLP-1 receptor; SC = subcutaneous; SGLT-2 = sodium-glucose cotransporter-2; T2D = type-2 diabetes.